Published 2019
| Version v1
Publication
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study
- Creators
- Conte, Benedetta
- Fabi, Alessandra
- Poggio, Francesca
- Blondeaux, Eva
- Dellepiane, Chiara
- D'Alonzo, Alessia
- Buono, Giuseppe
- Arpino, Grazia
- Magri, Valentina
- Naso, Giuseppe
- Presti, Daniele
- Mura, Silvia
- Fontana, Andrea
- Cognetti, Francesco
- MOLINELLI, CHIARA
- Pastorino, Simona
- Bighin, Claudia
- Miglietta, Loredana
- Boccardo, Francesco
- Lambertini, Matteo
- Del Mastro, Lucia
- Others:
- Conte, Benedetta
- Fabi, Alessandra
- Poggio, Francesca
- Blondeaux, Eva
- Dellepiane, Chiara
- D'Alonzo, Alessia
- Buono, Giuseppe
- Arpino, Grazia
- Magri, Valentina
- Naso, Giuseppe
- Presti, Daniele
- Mura, Silvia
- Fontana, Andrea
- Cognetti, Francesco
- Molinelli, Chiara
- Pastorino, Simona
- Bighin, Claudia
- Miglietta, Loredana
- Boccardo, Francesco
- Lambertini, Matteo
- Del Mastro, Lucia
Description
T-DM1 improves progression-free survival (PFS) and overall survival (OS) in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer progressing on prior trastuzumab plus a taxane. A paucity of data is available on T-DM1 efficacy after dual anti-HER2 blockade with pertuzumab and trastuzumab plus a taxane, which represents the current first-line standard of care. The present study is a retrospective/prospective evaluation of the efficacy and activity of second-line T-DM1 after front-line pertuzumab-based therapy.
Additional details
- URL
- http://hdl.handle.net/11567/986330
- URN
- urn:oai:iris.unige.it:11567/986330
- Origin repository
- UNIGE